

Ulcerative Colitis

**A study in the use of etrolizumab in patients with ulcerative colitis
(Eucalyptus)**

Evaluate the Efficacy and Safety of rhuMAb Beta7 in Patients With Moderate to Severe Ulcerative Colitis

Trial Status
Completed

Trial Runs In
11 Countries

Trial Identifier
NCT01336465 GP27778
ABS4986g

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This Phase II study is a randomized, double-blind, placebo-controlled multicenter study to evaluate the efficacy and safety of rhuMAb Beta7 in patients with moderate to severe ulcerative colitis.

Genentech, Inc.
Sponsor

Phase 2
Phase

NCT01336465 GP27778 ABS4986g
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
≥18 Years & ≤ 75 Years

Healthy Volunteers
No